Bachy E., Maurer M. J., Habermann T. M. et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132, 49–58 (2018).
Casulo C., Byrtek M., Dawson K. L. et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 2516–2522 (2015).
Durand A, Rossi C. Lymphome folliculaire, facteurs de risque en RCP : que retenir du passé et du présent, qu’attendre du futur? Horizon Hémato – Vol.13 n°4 Décembre 2023.
Federico M., Bellei M., Marcheselli L. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 4555–4562 (2009).
Huet S., Tesson B., Jais J-P. et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 19, 549–561 (2018).
Li H, Wang M, Zhang Y, et al. Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT. Front. Oncol. 12. (2022).
Maurer M. J., Bachy E., Ghesquières H. et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am. J. Hematol. 91,1096–1101 (2016).
Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16(9);1111-1122 (2015).
Rodier C, Kanagaratnam L, Morland D, et al. Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab. HemaSphere 7, e861 (2023).
Rossi, C, Tosolini M, Gravelle P, et al. Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 107, 221–230 (2020).
Solal-Céligny P., Roy P., Colombat P. et al. Follicular Lymphoma International Prognostic Index. Blood 104, 1258–1265 (2004).
Van de Schans SAM, Steyerberg EW, Nijziel MR, et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol. 2009 Oct;20(10):1697-702.